
Alkermes' Nemvaleukin Clinical Program

Nemavleukin alfa (nemvaleukin) is Alkermes' novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, which is being evaluated as a potential treatment for cancer. The clinical development program is comprised of clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin as monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors.



ARTISTRY 6 🔍

Evaluating efficacy, safety and tolerability; assessing as monotherapy.

Cancer/Tumor Type: Advanced cutaneous and mucosal melanoma: unresectable and/or metastatic, previously treated with anti-PD-L1 +/- anti-CTLA-4 therapy.

ARTISTRY 7 Con Q

Evaluating efficacy, safety and tolerability; assessing monotherapy and in combination with pembrolizumab, compared to investigator choice chemotherapy.


Cancer/Tumor Type: Platinum-resistant ovarian cancer.



ш

strational

In August 2021, the U.S. FDA granted nemvaleukin both Orphan Drug Designation and Fast Track Designation for the treatment of mucosal melanoma. In October 2021, the U.S. FDA granted nemvaleukin Fast Track Designation for the treatment of platinum-resistant ovarian cancer.





ION-01 in collaboration with Fred Hutchinson Cancer Research Center

ARTISTRY 7 in collaboration with Merck. Partnership with the GOG Foundation and ENGOT to conduct the study

